Core Viewpoint - Resverlogix Corp. is currently under a management cease trade order application due to delays in completing its annual financial statements audit, which has resulted in a default on the filing deadline [1][2]. Group 1: Management Cease Trade Order (MCTO) Update - The application for the MCTO is still under review by the Alberta Securities Commission (ASC), with no decision made yet [1]. - The company has defaulted on the March 31, 2026 deadline for filing its annual audited financial statements and related documents due to the auditor's inability to complete the audit on time [1][2]. - The company is working with the auditor to resolve initial delays and is optimistic about completing the annual filings by April 10, 2026, although this cannot be assured [2]. Group 2: Implications of the Default - If the MCTO is granted, the CEO and CFO will be prohibited from trading the company's securities, while the general public can continue trading the company's common shares [3]. - The company is committed to satisfying the alternative information guidelines under NP 12-203, including issuing bi-weekly default status reports until the annual filings are completed [4]. Group 3: Company Background - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company specializing in epigenetics and aims to develop first-in-class therapies for chronic diseases [6]. - The company is focused on its lead epigenetic candidate, apabetalone, for treating cardiovascular disease and related conditions [7]. - Resverlogix's common shares are traded on the Toronto Stock Exchange under the ticker RVX [8].

Core Viewpoint - Resverlogix Corp. is experiencing delays in completing its year-end audit, which will prevent the company from meeting the March 31, 2026 deadline for filing its Annual Filings [1] Group 1: Audit and Filing Delays - The company anticipates it will not meet the March 31, 2026 deadline for filing Annual Audited Financial Statements, Annual Information Form, and Management Discussion & Analysis for the year ended December 31, 2025 [1] - The auditor has indicated that the audit of the annual financial statements is unlikely to be completed by the deadline, with an expected completion date of April 10, 2026 [1] Group 2: Management Cease Trade Order - Resverlogix has applied to the Alberta Securities Commission for a management cease trade order (MCTO) that would restrict the trading of the company's securities by its CEO and CFO until the Annual Filings are submitted [2] - The ASC has not yet made a decision on the MCTO application, which could either be granted or result in an issuer cease trade order if delays continue [2] Group 3: Compliance and Reporting - The company is committed to completing the Annual Filings as soon as possible and will issue a news release once they are filed [3] - Until the Annual Filings are submitted, the company will adhere to guidelines set out in NP 12-203, including bi-weekly default status reports [3] Group 4: Insider Trading Blackout - Members of the company's management and other insiders are subject to an insider trading blackout until the Annual Filings are completed [4] - There have been no material business developments since the interim financial reports were filed on November 13, 2025 [4] Group 5: Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases [5] - The company is a leader in epigenetics and is developing a new class of therapies aimed at regulating disease-causing gene expression, particularly focusing on cardiovascular disease and post COVID-19 conditions [6]

Company Overview - Resverlogix Corp. is a Calgary-based late-stage biotechnology company founded in 2001, specializing in epigenetics and aiming to develop first-in-class therapies for chronic diseases [4]. - The company is focused on creating a new class of epigenetic therapies to regulate the expression of disease-causing genes, particularly targeting cardiovascular disease and post COVID-19 conditions [5]. Recent Financial Activity - Resverlogix announced the completion of a $2.8 million shares-for-interest private placement, where an immediate family member of the Chairman and CEO subscribed for 28,000,000 common shares at CAD$0.10 per share [1][2]. - Following this transaction, the Subscriber holds approximately 9.7% of Resverlogix's common shares, which are subject to a four-month hold period [2]. Debt Settlement - The shares-for-interest transaction was executed after the settlement of CAD$2.8 million of accrued interest owed to the Subscriber by Zenith Capital Corp., which was assigned to the Subscriber from Resverlogix's debt to Zenith [2]. Market Information - Resverlogix's common shares are traded on the Toronto Stock Exchange under the ticker symbol RVX [6].

Core Insights - Resverlogix Corp. has appointed Mr. Bradley Glass to its board of directors, bringing extensive legal and business experience to the company [1][3]. Company Overview - Resverlogix, founded in 2001, is a Calgary-based late-stage biotechnology company focused on developing first-in-class therapies for chronic diseases, particularly in the field of epigenetics [4]. - The company is developing a new class of epigenetic therapies aimed at regulating disease-causing gene expression, with a focus on improving patients' lives affected by serious illnesses such as cardiovascular disease [5]. Strategic Partnerships - Resverlogix has partnered with EVERSANA™ to facilitate the rapid commercialization of its lead candidate, apabetalone, for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States [6].